Those investments included a 67 million pound upgrade to GSK's manufacturing site in Montrose, Scotland, to beef up production of active pharmaceutical ingredients.

Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future ...

The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

The Moderna lawsuits echo similar claims made by GSK when it sued Pfizer and BioNTech for allegedly infringing upon the company’s mRNA patents back in April. At the time, Pfizer voiced ...

Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...